Abstract 4444
Background
Burn-Out Syndrome (BOS) in oncology nurses, has few experiences reported about its incidence and impact in its three different areas: emotional and physical exhaustion, cynism and despersonalization and no personal nor profesional fulfillment. There is a lack of resources for its diagnosis and management, although it impacts negatively in the patient attention/ care quality and the quality of institutional processes, added the personal impact in personal workers lives. Our objective was to determine the incidence of the BOS in our workers, analyze its causes and reduce in 20% the percentage of workers suffering or at risk of suffering BOS.
Methods
23 nurses / nurse assistants from Medical Oncology Department at University General Hospital of Valencia fulfilled an anomized questionnaire that included personal details, the GHQ-12 evaluation and the Maslach index questions; both at baseline and after each intervention. Causes of BOS were analysed, and process map and Ishikawa fish-bone scheme were designed. Interventions were carried in consequence. Data analyze through SPSS.
Results
23 subjects, 87% women, 47 years old median age. 15 at ward, 8 at clinic. 90% > 5 years in Oncology. At baseline, 75% GHQ-12 good health. Maslach index: 70%, 45% and 55% in risk (medium+high) of BOS related to exhaustion, despersonalization or fulfillment, respectively. In exhaustion, 35% medium risk, 35% high risk of BOS. Priority-matrix development, ergonomy tips and self-improvement tools identified as adequated interventions. After ergonomy tips intervention, 90% GHQ-12 good health, 15% exhaustion medium risk and 50% high risk; 65% at risk of BOS related to exhaustion. Improvement of 5% lowering risk of suffering BOS.
Conclusions
BOS is complex to measure due to answer subjetivity. We have healthier workers, but although levels of exhaustion have decreased, those who were already exhausted are worse than before. Possible causes: renovation work on the clinic, labor inestability, local holidays during evaluation. Self-improvement tools sessions are now being held to reduce risk ot BOS. Reevaluation of activity will be definitory of its success.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
2241 - KEYNOTE-641: Phase 3 Study of Pembrolizumab (pembro) Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: Julie Graff
Session: Poster Display session 3
Resources:
Abstract